Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research…

Read More

Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that…

Read More

Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference

Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare…

Read More